Mk-677 (Ibutamoren) — reference
Orally active non-peptide ghrelin-receptor agonist that raises GH and IGF-1.
Regulatory status
Not FDA-Approved. Never FDA-approved despite completing multiple clinical trials. Sold widely as a “research chemical” or mislabelled as a supplement. Banned by WADA.
Reported cautions
Pharmacokinetics
Published figures give an elimination half-life of ~24 hours. Long for a GH secretagogue — the reason it's dosed once daily and is orally active.
This figure is tagged PK study in our evidence system. This figure comes from a published pharmacokinetic study rather than a label or registration trial. Sample sizes in such studies are often small and figures vary between them, so treat the number as a range rather than a constant. You can see the shape this implies between doses in the Half-Life Visualizer, and compare it against every other compound in the Half-Life Data Table. Our sourcing page explains what each tier means.
Remember that an estimated curve is a model built from a population figure, not a measurement of your blood. Individual clearance varies, and for depot injections the figure describes release from the injection site rather than the compound clearing. Half-life explained →
What Peptide Plug does and does not publish
This page carries regulatory status, general context and published pharmacokinetics. It carries no dose, frequency or cycle information — that is a deliberate editorial line, because dosing is a clinical decision rather than reference data. We also do not sell, supply, source or link to vendors for any compound.
Frequently asked
Is Mk-677 (Ibutamoren) FDA-approved?
What is the half-life of Mk-677 (Ibutamoren)?
How reliable is that half-life figure?
What cautions are associated with Mk-677 (Ibutamoren)?
Does Peptide Plug publish dosing for Mk-677 (Ibutamoren)?
Does Peptide Plug sell Mk-677 (Ibutamoren)?
Related tools
Free, no account required.